Biomerieux Sa · EURONEXT:BIM
Biomerieux Sa — FY2025 Earnings Presentation
26 slides from Biomerieux Sa's earnings presentation, Feb 27, 2026
Slide 1: Full Year 2025 Financial Performance
Full Year 2025 Financial Performance Pierre BOULUD - CHIEF EXECUTIVE OFFICER Guillaume BOUHOURS - CHIEF FINANCIAL OFFICER February 27th, 2026 PIONEERING DIAGNOSTICS
Slide 2: Disclaimers
Disclaimers This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérie
Slide 3: FY 2025 Business highlights
FY 2025 Business highlights PIONEERING DIAGNOSTICS
Slide 4: FY 2025 Key highlights
FY 2025 Key highlights CONTRIBUTIVE FREE SALES EBIT CASHFLOW €4,070m €728m €462m +6.2%1 17.9% +40% vs 2024 of sales Cash positive ▪ Solid sales dynamic significantly outpacing market growth | +7.8% excluding China ▪ +16% organic CEBIT growth1 | Simplification initiatives on track and delivering resu
Slide 5: 2025 Sales: +6.2% growth, driven by the four GO.28 growth drivers
2025 Sales: +6.2%1 growth, driven by the four GO.28 growth drivers BIOFIRE® Non-Respiratory SPOTFIRE® €598m | +10%1 €168m | +84%1 ▪ +30% in net unit installations (+1,800) in 2025 vs 2024 | ▪ Volumes rose twofold | Indirect: 60% of US sales Total Installed Base of 28.5k units (+7% vs 2024) ▪ 6,400 i
Slide 6: 2025 Sales: BIOFIRE RP & Immunoassays
2025 Sales: Biofire® RP & Immunoassays for Growth BIOFIRE® Respiratory Panels Immunoassays €813m | +1%1 €308m | -6%1 ▪ 2025 epidemiology broadly in line with 2024 strong level ▪ Flat sales excl. China & PCT2 ▪ Limited price erosion (<2%) ▪ Mid teens sales growth in instruments (VIDAS® KUBE) 1 At con
Slide 7: 2025 CEBIT: +16% driven by the GO.Simple initiatives
2025 CEBIT: +16%1 driven by the GO.Simple initiatives Simple Strengthened 50+ initiatives operating leverage COGS G&A / R&D S&M • Internalization • IT nearshoring • On-going transformation of Instruments & raw materials Global Customer Service • Processes automation • Automation • “Launch Excellence
Slide 8: 2025: Significant progresses across core pillars
2025: Significant progresses across core pillars All data as of December 2025 Responsible PLANET EMPLOYEES HEALTHCARE EXTENDED HEALTH ECOSYSTEM COMPANY Collaborative projects ≥1% +30% -50% Lost Day Incident Rate of net income Group share with patient associations patient results1 GHG absolute emissi
Slide 9: On track to achieve the ambition
On track to the achieve the ambition ACTUAL ambition 2024 / 2025 Sales Growth (CAGR) +7%1CAGR for Growth +8%1 CEBIT growth at least 10%1 2024 : +20%1 2025: +16%1 every year Simple 2025 CEBIT margin +340bps1 +260bps2 vs 2023 by 2028 2025 engagement Survey Strengthened Stronger Top 5% in the industry
Slide 10: Financial Performance
FY 2025 Financial Performance PIONEERING DIAGNOSTICS
Slide 11: 2025 Sales: +6.2% significantly exceeding the market
2025 Sales: +6.2%* significantly exceeding the market SPOTFIRE €168m (+84%*) ▪ 6,400 instruments at the end of Dec. 2025 ▪ +3,400 units installations in 2025 MICROBIOLOGY +4%* ▪ +6.3%* excl. China impacted by market softness BIOFIRE® Instr. & Services +16%* ▪ +2pp price increase BIOFIRE® Non-RP +10%
Slide 12: FY 2025 sales by geography
FY 2025 sales by geography EMEA +5%* NORAM +8%* €1,314m 32% of sales €1,847m • DD increase in BIOFIRE® 45% of sales non-respiratory panels • Solid growth SPOTFIRE®, • MSD rise in microbiology Industrial App., BIOFIRE® • Industrial App. +7% non-respiratory panels • LSD growth BIOFIRE® RP +1.5%* ASPAC
Slide 13: FY 2025 P&L: CEBIT up +16% like-for-like
FY 2025 P&L: CEBIT up +16% like-for-like1 reflecting good progresses of GO.28 FY % FY % % % In €m sales sales Change Change LFL(1) 2025 2024 Net sales 4,070 3,980 + 2.3% + 6.2% Gross profit 2,309 56.7% 2,215 55.7% + 4.2% + 7.9% SG&A -1,111 -27,3% -1,099 -27,6% +1.2% +4.1% R&D -507 - 12.5% -491 - 12.
Slide 14: FY 2025 P&L: +9% increase in adjusted EPS
FY 2025 P&L: +9% increase in adjusted EPS FY % FY % % change In €m sales sales 2025 2024 as reported CEBIT 728 17.9% 673 16.9% +8.2% Amortization of acquired intangible assets & related expenses -167 -58 Other non-recurring income (expenses) -40 -26 Operating income 521 12.8% 589 14.8% -11.5% Net fi
Slide 15: Strong cash flow generation: +40% vs 2024
STRONG CASH FLOW GENERATION: +40% vs 2024 • Inventories (-€10m) Millions € December 2025 December 2024 • Receivables (-29m): activity increase & collection improvement • Other WCR items (-€30m) : payment of some 2024 EBITDA (1) 960 914 social debts Working capital requirement - 66 - 47 Tax payment &
Slide 16: 2025 Capex: ~€330m to nurture future growth
2025 Capex: ~€330m to nurture future growth Biofire® pouches: automated manuf. (USA) Manufacturing Enzymes’internalization (France) ~€220m • Capacity increase • Automation • Internalization Instrument’s placements ~€110m Spotfire® instruments Mainly Spotfire & placed with US BACT/Alert BACT/Alert® i
Slide 17: Point of Need automated flow cytometry solutions for cell and gene therapy
« Point of Need » automated flow cytometry solutions for cell and gene therapy quality control • Strengthens bioMérieux Pharma QC offer in the fast-growing Cell and Gene Therapy segment • Enterprise Value: ~€45m • 2029: ~€20m targeted sales with breakeven Easy to use Available at the “Point of Need”
Slide 18: 2026 Outlook
2026 Outlook PIONEERING DIAGNOSTICS
Slide 19: 2026 Key Product Launches
2026 Key Product Launches Q1 26: CE Filing Q4 26 / Q1 27: Commercial Launch Clinical study in progress 2028: Commercial Launch SPOTFIRE® Q3 26: FDA filing VAGINITIS Q4 26 / Q1 27: Commercial Launch SPOTFIRE® H1 26: CE Marking Mini Panels B I O M É R I E U X
Slide 20: 2026 Outlook: Guidance key elements
2026 OUTLOOK GUIDANCE KEY ELEMENTS (% evolution at constant exchange rates) REVENUES ▪ BIOFIRE® non-RP: around +10% | Cross selling & OUS SALES expansion +5.0% to +7.0% ▪ Spotfire: +40% to +60% | further installed base expansion and intensity of the flu season Organic ▪ Microbiology: ~+3% to +5% | C
Slide 21: 2026 Outlook: FX impact
2026 OUTLOOK: FX impact 2026 CEBIT sensitivity to FX forecasted CEBIT FX impact FX exposure on Estimated Impact of +/-5% Current rate* 2026 forecasted Currency revenues FX variation vs EUR on vs FX impact (2025 basis) CEBIT 2025 average (€m) USD & related 47% +/- €12m 4% ~-11 Indian Rupie 4% +/- €4m
Slide 22: Beyond 2026
Beyond 2026 PIONEERING DIAGNOSTICS
Slide 23: CSR: new ambitions and milestones
CSR: new ambitions and milestones Responsible Defining a new cycle of CSR objectives with major milestones for 2028 and an enhanced focus on our impact on HEALTH and the PLANET CO2 reduction Reinforced AMS/AMR impact through increased accessibility -35% | Scopes 1&2 by 2028 -35% | Scope 3 by 2034 +6
Slide 24: Confirmation of the GO.28 ambition
FOR INTERNAL USE ONLY CONFIRMATION OF THE GO.28 AMBITION ACTUAL 2026 ambition SALES 2024 /2025 ~+6%1 +7% growth1 +8% midpoint CAGR cEBIT 2024 2025 growth1 +20% +16% ≥+10% at least 10% every year cEBIT 2024 2025 margin +150 bps1 +110bps2 ~+70bps +340 => ~+500 bps1 bps1 vs 2023 1 at Constant Exchange
Slide 25: Pioneering Diagnostics
BIOMERIEUX PIONEERING DIAGNOSTICS
Slide 26: 2028 CSR objectives
2028 CSR objectives Responsible ACCESSIBILITY NET ZERO CO2e BY 2050 SAFETY ETHICS PHILANTHROPY ≥1.5% +60% patient TR2IR* & Mental of net income SCOPES 1&2 : -35% EcoVadis results vs 2023 Health Index attributable to the parent SCOPE 3 : -35% by 2034 yoy improvement Ethics score company supporting AM